Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciprofloxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.98 |
| ▸ | LMNA | P02545 | 5/20 | 0.98 |
| ▸ | HPGD | P15428 | 4/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | TOP2A | P11388 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | BRD4 | O60885 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.61 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.61 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciprofloxacin SCHEMBL7994990 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL7992974 | 1.00 | KDM4E (0.98) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL27004 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL1281819 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL184706 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL23064249 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL8530004 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2325952 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL2636760 | 0.99 | KDM4E (0.96) | KDM4EALDH1A1LMNAHPGDHSD17B10 | |
| Ciprofloxacin SCHEMBL4459712 | 0.99 | KDM4E (1.00) | KDM4EALDH1A1LMNAHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106794144-B | Sterilization of ciprofloxacin compositions | 奥德纳米有限公司 | 2020-07-17 | — | — | CN | claimed |
| CN-104352429-B | For treating the controlled release antimicrobial compositions of otic conditions and method | 奥德纳米有限公司 | 2018-05-18 | — | — | CN | claimed |
| US-9757484-B2 | Sterilization of ciprofloxacin composition | OTONOMY, INC. (US) | 2017-09-12 | — | — | US | claimed |
| CN-106794144-A | Sterilization of ciprofloxacin compositions | 奥德纳米有限公司 | 2017-05-31 | — | — | CN | claimed |
| EP-3164115-A1 | STERILIZATION OF CIPROFLOXACIN COMPOSITION | Otonomy, Inc. (US) | 2017-05-10 | — | — | EP | claimed |
| US-20160279274-A1 | STERILIZATION OF CIPROFLOXACIN COMPOSITION | ALK-ABELLÓ, INC. | 2016-09-29 | — | — | US | claimed |
| WO-2016004231-A1 | STERILIZATION OF CIPROFLOXACIN COMPOSITION | OTONOMY, INC. (US) | 2016-01-07 | — | — | WO | claimed |
| US-20160000948-A1 | STERILIZATION OF CIPROFLOXACIN COMPOSITION | ALK-ABELLÓ, INC. | 2016-01-07 | — | — | US | claimed |
| US-9220796-B1 | Sterilization of ciprofloxacin composition | OTONOMY, INC. (US) | 2015-12-29 | — | — | US | claimed |
| CN-104352429-A | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTONOMY INC | 2015-02-18 | — | — | CN | claimed |
| US-20120277199-A1 | Modulation of Gel Temperature of Poloxamer-Containing Formulations | OTONOMY, INC. (US) | 2012-11-01 | — | — | US | claimed |
| EP-2490722-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | Otonomy, Inc. (US) | 2012-08-29 | — | — | EP | claimed |
| WO-2011049960-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| WO-2011050206-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| WO-2011049958-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | claimed |
| US-20220233522-A1 | CIPROFLOXACIN OTIC COMPOSITION AND KITS AND METHOD FOR USING SAME | ALK ABELLO INC (US) | 2022-07-28 | — | — | US | disclosed |
| US-11246863-B2 | Ciprofloxacin otic composition and kits and method for using same | ALK-ABELLÓ, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-5286754-A | Microcrystalline cellulose, moist starch, crosslinked polyvinylpyrrolidone, silicon dixode and magnesium stearate | BAYER AKTIENGESELLSCHAFT (DE) | 1994-02-15 | — | — | US | disclosed |
| US-5023257-A | Related to ciprofloxacin, in the form of oily suspension; bacterial infections | BAYER AKTIENGESELLSCHAFT (DE) | 1991-06-11 | — | — | US | disclosed |
| CN-1037272-A | The intramuscular injection agent of gyrase inhibitor | BAYER AG (DE) | 1989-11-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279274-A1 | STERILIZATION OF CIPROFLOXACIN COMPOSITION | SPOUT1, COX5B, QARS1 | KDM4E 1546/4885ALDH1A1 691/4885LMNA 759/4885 |
| US-20160000948-A1 | STERILIZATION OF CIPROFLOXACIN COMPOSITION | SPOUT1, COX5B, QARS1 | KDM4E 1546/4885ALDH1A1 691/4885LMNA 759/4885 |
| US-20220233522-A1 | CIPROFLOXACIN OTIC COMPOSITION AND KITS AND METHOD FOR USING SAME | P2RX7, OTC, P2RX6 | KDM4E 1589/4885ALDH1A1 2618/4885LMNA 2447/4885 |
| US-11246863-B2 | Ciprofloxacin otic composition and kits and method for using same | P2RX7, OTC, P2RX6 | KDM4E 1589/4885ALDH1A1 2618/4885LMNA 2447/4885 |
| US-20120277199-A1 | Modulation of Gel Temperature of Poloxamer-Containing Formulations | PTGIR, HSPH1, HSP90AA1 | KDM4E 4728/4885ALDH1A1 3364/4885LMNA 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.